Cambria Investment Boosts Eli Lilly Stake by 255%

Hedge fund increases position in pharmaceutical giant during Q3 2025.

Mar. 5, 2026 at 9:40am

Got story updates? Submit your updates here. ›

Cambria Investment Management L.P. significantly increased its stake in Eli Lilly and Company (NYSE:LLY) during the third quarter of 2025, purchasing an additional 1,026 shares to boost its total position by 255.2%. The hedge fund now owns 1,428 shares of the pharmaceutical company's stock, valued at $1.09 million as of its most recent SEC filing.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs and therapies. Cambria's increased investment suggests the hedge fund sees strong growth potential in Lilly's business and pipeline, which could signal broader investor confidence in the company's future performance.

The details

According to the SEC filing, Cambria Investment Management purchased the additional 1,026 shares of Eli Lilly during Q3 2025, bringing its total position to 1,428 shares. This represents a 255.2% increase from the prior quarter. Cambria's investment in Lilly is now valued at $1.09 million, underscoring the hedge fund's bullish outlook on the pharmaceutical firm.

  • Cambria Investment Management increased its Eli Lilly stake in Q3 2025.

The players

Cambria Investment Management L.P.

A hedge fund that manages investments across various asset classes, including equities, fixed income, and alternatives.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, known for developing innovative drugs and therapies.

Got photos? Submit your photos here. ›

The takeaway

Cambria Investment Management's significant increase in its Eli Lilly stake suggests the hedge fund sees strong growth potential in the pharmaceutical company's business and pipeline, which could signal broader investor confidence in Lilly's future performance.